Literature DB >> 25839221

A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Jay R McCoy1, Janess M Mendoza, Kristin W Spik, Catherine Badger, Alan F Gomez, Connie S Schmaljohn, Niranjan Y Sardesai, Kate E Broderick.   

Abstract

The identification of an effective and tolerable delivery method is a necessity for the success of DNA vaccines in the clinic. This article describes the development and validation of a multi-headed intradermal electroporation device which would be applicable for delivering multiple DNA vaccine plasmids simultaneously but spatially separated. Reporter gene plasmids expressing green and red fluorescent proteins were used to demonstrate the impact of spatial separation on DNA delivery to increase the number of transfected cells and avoid interference through visible expression patterns. To investigate the impact of plasmid interference on immunogenicity, a disease target was investigated where issues with multi-valent vaccines had been previously described. DNA-based Hantaan and Puumala virus vaccines were delivered separately or as a combination and the effect of multi-valence was determined by appropriate assays. While a negative impact was observed for both antigenic vaccines when delivered together, these effects were mitigated when the vaccine was delivered using the multi-head device. We also demonstrate how the multi-head device facilitates higher dose delivery to the skin resulting in improved immune responses. This new multi-head platform device is an efficient, tolerable and non-invasive method to deliver multiple plasmid DNA constructs simultaneously allowing the tailoring of delivery sites for combination vaccines. Additionally, this device would allow the delivery of multi-plasmid vaccine formulations without risk of impacted immune responses through interference. Such a low-cost, easy to use device platform for the delivery of multi-agent DNA vaccines would have direct applications by the military and healthcare sectors for mass vaccination purposes.

Entities:  

Keywords:  DNA vaccine; dermal; electroporation; multi-agent; noninvasive; tolerable

Mesh:

Substances:

Year:  2015        PMID: 25839221      PMCID: PMC4514302          DOI: 10.4161/21645515.2014.978223

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  41 in total

1.  Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.

Authors:  A Kjerrström; J Hinkula; G Engström; V Ovod; K Krohn; R Benthin; B Wahren
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

2.  Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.

Authors:  Eiji Konishi; Saori Kosugi; Jun-ichi Imoto
Journal:  Vaccine       Date:  2005-11-15       Impact factor: 3.641

3.  Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates.

Authors:  Jay W Hooper; David M Custer; Jeffrey Smith; Victoria Wahl-Jensen
Journal:  Virology       Date:  2005-12-27       Impact factor: 3.616

4.  Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).

Authors:  J S Yang; J J Kim; D Hwang; A Y Choo; K Dang; H Maguire; S Kudchodkar; M P Ramanathan; D B Weiner
Journal:  J Infect Dis       Date:  2001-08-29       Impact factor: 5.226

5.  Stochastic model for electric field-induced membrane pores. Electroporation.

Authors:  I P Sugar; E Neumann
Journal:  Biophys Chem       Date:  1984-05       Impact factor: 2.352

6.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Authors:  Spyros A Kalams; Scott D Parker; Marnie Elizaga; Barbara Metch; Srilatha Edupuganti; John Hural; Stephen De Rosa; Donald K Carter; Kyle Rybczyk; Ian Frank; Jonathan Fuchs; Beryl Koblin; Denny H Kim; Patrice Joseph; Michael C Keefer; Lindsey R Baden; John Eldridge; Jean Boyer; Adam Sherwat; Massimo Cardinali; Mary Allen; Michael Pensiero; Chris Butler; Amir S Khan; Jian Yan; Niranjan Y Sardesai; James G Kublin; David B Weiner
Journal:  J Infect Dis       Date:  2013-07-08       Impact factor: 5.226

7.  Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device.

Authors:  Feng Lin; Xuefei Shen; Gleb Kichaev; Janess M Mendoza; Maria Yang; Philip Armendi; Jian Yan; Gary P Kobinger; Alexander Bello; Amir S Khan; Kate E Broderick; Niranjan Y Sardesai
Journal:  Hum Gene Ther Methods       Date:  2012-07-13       Impact factor: 2.396

8.  A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Authors:  David Hallengärd; Andreas Bråve; Maria Isaguliants; Pontus Blomberg; Jenny Enger; Richard Stout; Alan King; Britta Wahren
Journal:  Genet Vaccines Ther       Date:  2012-08-08

9.  Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation.

Authors:  Kate E Broderick; Amy Chan; Feng Lin; Xuefei Shen; Gleb Kichaev; Amir S Khan; Justin Aubin; Tracy S Zimmermann; Niranjan Y Sardesai
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-14       Impact factor: 10.183

10.  Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.

Authors:  Yen Cu; Kate E Broderick; Kaustuv Banerjee; Julie Hickman; Gillis Otten; Susan Barnett; Gleb Kichaev; Niranjan Y Sardesai; Jeffrey B Ulmer; Andrew Geall
Journal:  Vaccines (Basel)       Date:  2013-08-22
View more
  3 in total

1.  A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting.

Authors:  Tiphany Chrun; Sandra Lacôte; Céline Urien; Luc Jouneau; Céline Barc; Edwige Bouguyon; Vanessa Contreras; Audrey Ferrier-Rembert; Christophe N Peyrefitte; Nuria Busquets; Enric Vidal; Joan Pujols; Philippe Marianneau; Isabelle Schwartz-Cornil
Journal:  NPJ Vaccines       Date:  2018-04-20       Impact factor: 7.344

2.  Adipose tissue: a new target for electroporation-enhanced DNA vaccines.

Authors:  P D Fisher; C J Brambila; J R McCoy; W B Kiosses; J M Mendoza; J Oh; B S Yung; K Schultheis; T R F Smith; K E Broderick
Journal:  Gene Ther       Date:  2017-11-06       Impact factor: 5.250

3.  Safe and efficient novel approach for non-invasive gene electrotransfer to skin.

Authors:  Lise Pasquet; Sophie Chabot; Elisabeth Bellard; Bostjan Markelc; Marie-Pierre Rols; Jean-Paul Reynes; Gérard Tiraby; Franck Couillaud; Justin Teissie; Muriel Golzio
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.